Huge leap made in search for Huntington’s disease treatment
- Scientists have achieved a "groundbreaking" milestone by slowing the progression of Huntington's disease for the first time with a new gene therapy.
- The treatment, named AMT-130, is delivered via brain surgery and is expected to last a patient's lifetime after a single dose.
- Early-stage clinical trials involving 29 patients showed that those receiving a high dose experienced 75 per cent less disease progression after 36 months.
- Experts from University College London (UCL), including Professor Ed Wild and Professor Sarah Tabrizi, hailed the findings as potentially "world-changing" and the most convincing evidence to date for a disease-modifying effect.
- The development offers hope for patients, with the potential to preserve daily function, extend working lives, and significantly slow the disease, which currently has no cure.
Bookmark popover
Removed from bookmarks